Abraham Ceesay - Sep 8, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
President
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Sep 8, 2022
Transactions value $
-$371,329
Form type
4
Date filed
9/12/2022, 04:24 PM
Previous filing
Aug 24, 2022
Next filing
Feb 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $253K +19.2K $13.17 19.2K Sep 8, 2022 Direct F1
transaction CERE Common Stock Sale -$624K -19.2K -100% $32.50 0 Sep 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -19.2K -5% $0.00 365K Sep 8, 2022 Common Stock 19.2K $13.17 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person.
F2 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.